Radius Health, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Radius Health, Inc. (NASDAQ:RDUS), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, on July 28, 2015, announced the closing of its previously announced public offering of 4,662,162 shares of common stock at a public offering price of $74.00 per share, including 608,108 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares of common stock.
J.P. Morgan, BofA Merrill Lynch and Deutsche Bank Securities are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager.
The offering was made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.